Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avogenx
Research Triangle Park, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Avogenx's primary program, remogliflozin etabonate, demonstrated HbA1c lowering greater than 1% with no significant adverse events in phase 2b clinical studies. The compound showed low incidence rates of genitourinary infections compared to other SGLT2 inhibitors and demonstrated strong postprandial glucose disposal with improvements in insulin sensitivity and beta cell function.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Brighthaven Ventures (BHV) - exclusive license agreement for remogliflozin development and commercialization
Beyond the preview
Go deeper on Avogenx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avogenx.